• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by AbbVie Inc.

    5/26/26 4:10:15 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001448074
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    ABBVIE INC.
    SEC File Number
    001-35565
    Address of Issuer
    1 North Waukegan Road
    North Chicago
    ILLINOIS
    60064-6400
    Phone
    847-932-7900
    Name of Person for Whose Account the Securities are To Be Sold
    ROBERT J ALPERN
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    130002781990.90176679282105/26/2026
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common05/06/2013Restricted StockIssuerCheckbox not checked253505/06/2013Not Applicable
    Common05/09/2014Restricted StockIssuerCheckbox not checked276405/09/2014Not Applicable
    Common05/08/2015Restricted StockIssuerCheckbox not checked218705/08/2015Not Applicable
    Common05/06/2016Restricted StockIssuerCheckbox not checked297405/06/2016Not Applicable
    Common05/05/2017Restricted StockIssuerCheckbox not checked254005/05/2017Not Applicable

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    05/26/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Robert Alpern

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV

    DatePrice TargetRatingAnalyst
    4/30/2026$234.00Neutral → Buy
    BofA Securities
    4/21/2026$262.00Buy
    Canaccord Genuity
    2/25/2026$260.00Outperform
    RBC Capital Mkts
    2/20/2026$275.00Overweight
    Barclays
    1/8/2026Outperform → Peer Perform
    Wolfe Research
    1/7/2026$240.00Neutral
    UBS
    12/10/2025$265.00Hold → Buy
    HSBC Securities
    11/13/2025$280.00Sector Outperform
    Scotiabank
    More analyst ratings

    $ABBV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Falk Thomas J was granted 1,118 shares, increasing direct ownership by 93% to 2,321 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    5/12/26 5:00:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Quaggin Susan E was granted 1,118 shares, increasing direct ownership by 44% to 3,643 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    5/12/26 5:00:23 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Rapp Edward J was granted 1,118 shares, increasing direct ownership by 2% to 45,964 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    5/12/26 5:00:25 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    SEC Filings

    View All

    SEC Form SD filed by AbbVie Inc.

    SD - AbbVie Inc. (0001551152) (Filer)

    6/1/26 5:17:13 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by AbbVie Inc.

    144 - AbbVie Inc. (0001551152) (Subject)

    5/26/26 4:10:15 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - AbbVie Inc. (0001551152) (Filer)

    5/12/26 5:01:51 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    AbbVie upgraded by BofA Securities with a new price target

    BofA Securities upgraded AbbVie from Neutral to Buy and set a new price target of $234.00

    4/30/26 7:15:05 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on AbbVie with a new price target

    Canaccord Genuity initiated coverage of AbbVie with a rating of Buy and set a new price target of $262.00

    4/21/26 7:30:27 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on AbbVie with a new price target

    RBC Capital Mkts initiated coverage of AbbVie with a rating of Outperform and set a new price target of $260.00

    2/25/26 7:48:26 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for DECNUPAZ issued to ABBVIE INC

    Submission status for ABBVIE INC's drug DECNUPAZ (ORIG-1) with active ingredient PIVEKIMAB SUNIRINE-PVZY has changed to 'Approval' on 05/27/2026. Application Category: BLA, Application Number: 761460, Application Classification:

    5/29/26 7:34:21 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

    NORTH CHICAGO, Ill., June 2, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026. Management will participate in a fireside chat at 9:40 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key th

    6/2/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

    Addition of VENCLYXTO plus acalabrutinib, with or without obinutuzumab, and VENCLYXTO plus ibrutinib supported by data from Phase 3 AMPLIFY trial, Phase 3 GLOW trial and Phase 2 CAPTIVATE trialFixed-duration VENCLYXTO-based combination regimens provide patients with additional CLL treatment options that may offer the potential for treatment-free intervals NORTH CHICAGO, Ill., May 29, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the European Commission (EC) has authorized an expanded label for VENCLYXTO® (venetoclax) to include use in combination with acalabrutinib (with or without obinutuzumab) and use in combination with ibrutinib for the treatment of adult patients with pre

    5/29/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

    - DECNUPAZ is the first and only antibody-drug conjugate (ADC) approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) that is initiated in an outpatient setting- DECNUPAZ marks AbbVie's first ADC approved for blood cancerNORTH CHICAGO, Ill., May 27, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved DECNUPAZTM (pivekimab sunirine-pvzy) for the treatment of adult patients with BPDCN, an ultra-rare and aggressive hematologic malignancy with limited treatment options. The approval is supported by data from the Phase 1/2 CADENZA trial, a global study evaluating the safety and efficacy of DECNUPAZ for BPDCN. "For patien

    5/27/26 6:18:00 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Leadership Updates

    Live Leadership Updates

    View All

    AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

    Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to

    2/14/25 7:40:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

    11/5/24 7:05:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

    11/5/24 7:00:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ABBV
    Financials

    Live finance-specific insights

    View All

    AbbVie Reports First-Quarter 2026 Financial Results

    Reports First-Quarter Diluted EPS of $0.39 on a GAAP Basis, a Decrease of 45.8 Percent; Adjusted Diluted EPS of $2.65, an Increase of 7.7 Percent; These Results Include an Unfavorable Impact of $0.41 Per Share Related to Acquired IPR&D and Milestones Expense  Delivers First-Quarter Net Revenues of $15.002 Billion, an Increase of 12.4 Percent on a Reported Basis or 10.3 Percent on an Operational Basis First-Quarter Global Net Revenues from the Immunology Portfolio Were $7.290 Billion, an Increase of 16.4 Percent on a Reported Basis, or 14.3 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $4.483 Billion; Global Rinvoq Net Revenues Were $2.119 Billion; Global Humira Net Revenu

    4/29/26 7:47:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie to Host First-Quarter 2026 Earnings Conference Call

    NORTH CHICAGO, Ill., March 31, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its first-quarter 2026 financial results on Wednesday, April 29, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas

    3/31/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Declares Quarterly Dividend

    NORTH CHICAGO, Ill., Feb. 19, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.73 per share.  The cash dividend is payable May 15, 2026, to stockholders of record at the close of business on April 15, 2026.Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of

    2/19/26 9:37:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/13/24 4:55:55 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    1/25/24 4:59:27 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/9/23 10:54:46 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care